XClose

Early Phase Cancer Trials Programme at UCL and UCLH

Home
Menu

Gastro-Intestinal Trials

A LIST OF OUR EARLY PHASE gastro-intestinal TRIALS WHICH ARE OPEN TO RECRUITMENT AT UNIVERSITY COLLEGE LONDON HOSPITALs

To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.

 

NuTide302

A Phase Ib open label Study to assess NUC-3373 in patients with colorectal cancer:  A Phase Ib open label study to assess the safety and pharmacokinetics of NUC-3373, a nucleotide analogue, given in combination with standard agents used in colorectal cancer treatment

Local Project Reference:108215
Principal InvestigatorDr. Khurum Khan
Drug Class/ Treatment:

NUC-3373 (Nucleotide Analogue)

Part 3: Arm 3A - Combination with LV Q1W + Oxaliplatin + Bevacizumab

Patient Population:Colorectal Cancer
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

PORCUPINE1 (RXC004/002: REACT)

A Multi-arm, Phase II, Open-Label, Multicentre Study to Assess the Preliminary Efficacy of RXC004 in Monotherapy and in Combination with Nivolumab, in Patients with Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer who have Progressed following Therapy with Current Standard of Care (REACT study)

Local Project Reference:137631
Principal Investigator:Prof. John Bridgewater
Drug Class/ Treatment:

RXC004 (FGFR Inhibitor)

Monotherapy and/or Combination with Nivolumab (PD-1 Inhibiting IgG4 Monoclonal)

Patient Population:

RNF43/RSP

Colorectal Cancer

Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

 

Trials On-Hold to recruitment

PORCUPINE2 (RXC004/003)

A Modular, Phase II, Open-Label, Multicentre Study to Assess the Preliminary Efficacy and Safety of RXC004, in Patients with Advanced Solid Tumours that have Progressed following Therapy with Current Standard of Care

Local Project Reference:138861
Principal Investigator:Prof. John Bridgewater
Drug Class/ Treatment:

RXC004 (FGFR Inhibitor)

Monotherapy.

Patient Population:

Pancreatic Ductual Adenocarcinoma

Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)